Latest news with #Streamex
Globe and Mail
6 days ago
- Business
- Globe and Mail
BioSig Appoints Former OppenheimerFunds and Wafra Inc Executive, Mitch Williams, CFA, as Chief Investment Officer
Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig" or the 'combined company'), which today acquired Streamex Exchange Corporation ('Streamex') as its wholly owned subsidiary, announced the appointment of Mitch Williams, CFA, as Chief Investment Officer, significantly bolstering the combined company's leadership team and advancing its mission to tokenize real world assets and bring commodity markets on-chain. Key Highlights of the Appointment: Mr. Mitch Williams, former OppenheimerFunds and Wafra Inc. executive and Strategic Advisor to Streamex, will be appointed Chief Investment Officer of the combined company. Mr. Williams brings over 20 years of experience in capital markets, having held senior executive roles at OppenheimerFunds, and Wafra Inc. At Wafra Inc., Mr. Williams grew assets under by more than 3-fold and consistently delivered asymmetric returns with top-quartile performance over all rolling five-year periods. At OppenheimerFunds, Mr. Williams was the top-ranked equity analyst and led the firm's flagship fund. Mr. Williams will help lead Streamex in its strategic positioning within the US$142.851 trillion global commodity market, aiming to unlock new value by bringing commodities on-chain through secure and scalable real world asset tokenization solutions. As CIO, Mitch will lead the combined company's strategic vision and commodity tokenization initiatives, while overseeing key areas and reporting directly to Chief Executive Officer Henry McPhie. Mitch commented, 'As an early investor in Streamex and later a Strategic Advisor I have been consistently impressed with Henry, Morgan, and the team and the innovative platform they've built. As a believer in disruptive technology, I see RWA tokenization as an incredibly scalable technology. For me it is a leap forward in finding real world applications for blockchain- a technology whose value has only begun to be realized. As an investor, I see Streamex as one of the few pathways for investors interested in both a hedge against fiat currency regimes and recurring revenue model.' 'We are thrilled to welcome Mitch as our new Chief Investment Officer,' said Henry McPhie, Chief Executive Officer of the combined company. 'Mitch's exceptional record of delivering disciplined, high-return investment strategies over his career at large New York funds paired with his collaborative leadership style perfectly complements our culture and growth ambitions. I am confident that his vision will unlock new opportunities for our shareholders, and I couldn't be happier to have him join our leadership team.' About Mitch Williams In his over two decades on Wall Street, Mitch has had a front row seat for disruptive technologies and market innovation. From his early role during Web 1.0 at Credit Suisse on the Internet Financial Services team to high-profile positions at OppenheimerFund and Wafra Inc managing multi-billion dollar domestic and global teams and portfolios, Mitch has driven consistent value creation for both his clients and employers. At Wafra, Mitch grew assets under management by more than 3-fold during his tenure, delivering asymmetric returns characterized by upside capture consistently above 100% and downside capture below 100%. Under his lead Wafra achieved top-quartile performance for every rolling five-year period his team managed the Global Equity strategy. At OppenheimerFunds, he was a top-ranked analyst and took a leading role in managing one of the firm's flagship funds. As Chief Investment Officer at Streamex, Mitch will apply his deep capital markets expertise and strategic vision to shape the firm's direction. Prior to this role, he served as a Strategic Advisor on Capital Markets to Streamex, working closely with Streamex founders Henry, Morgan, and Mathew August to develop and implement transformative business strategies. Outside of his professional commitments, Mitch is an active mentor and speaker. He volunteers with the Michael Price Student Investment Fund at NYU's Stern School of Business and has spoken on investing at numerous leading universities. He holds an MBA from NYU Stern, where he was awarded the Stern Fellowship, and a BA from the University of Florida. About Streamex Exchange Corporation Streamex is a real-world asset (RWA) tokenization company focused in the commodities space. With the goal to bring commodity markets on chain, Streamex has developed primary issuance and exchange infrastructure that will revolutionize commodity finance. Streamex is led by a group of highly successful and seasoned executives from financial, commodities and blockchain industries. Streamex believes the future of finance lies in tokenization, innovative investment strategies, and decentralized markets. By merging advanced financial technologies with blockchain transparency, Streamex has created infrastructure and solutions that enhance liquidity, accessibility, and efficiency. Streamex's goal is to bridge the gap between traditional finance and the digital economy, unlocking new opportunities for investors and institutions worldwide. Forward Looking statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the acquisition of Streamex, whether shareholder approval of the transaction will be obtained and whether we will be able to maintain compliance with Nasdaq's listing criteria in connection with the acquisition and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled 'Risk Factors' in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.
Globe and Mail
6 days ago
- Business
- Globe and Mail
Streamex and BioSig Announce the Successful Closing of Share Exchange Transaction and Executive Leadership Changes Bringing a First-Mover Real World Asset Tokenization Company to the Nasdaq
Los Angeles, CA and Vancouver, BC, May 28, 2025 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (Nasdaq: BSGM) ("BioSig") and Streamex Exchange Corporation ("Streamex"), collectively referred to as the combined company, today announced successful completion of the previously disclosed share exchange transaction and executive leadership changes, forming a company specializing in the tokenization of real-world assets, with a focus on bringing commodities on-chain. Key Highlights of the Transaction: Streamex Exchange Corporation, a British Columbia corporation, will become a wholly owned subsidiary of BioSig through an exchange of outstanding shares of Streamex for new shares of BioSig common stock. The combined company will be led by Mr. Henry McPhie, Co-Founder and CEO of Streamex, who will serve as Chief Executive Officer and join the Board of Directors, guiding the organization through its next phase of growth. Mr. Morgan Lekstrom, Co-Founder and Chairman of Streamex, will serve as Chairman of the Board of the combined company. Mr. Anthony Amato, current CEO of BioSig, will transition from his role as Chief Executive Officer and continue to support the combined company as a member of its Board of Directors. Of highlight, Streamex is strategically positioned within the US$142.851 trillion global commodity market, aiming to unlock new value by bringing commodities on-chain through secure and scalable real world asset tokenization solutions. Together, Henry and Morgan with Anthony's support will lead the combined company through its next phase of strategic growth, bringing deep industry expertise and a shared vision for transforming the future of real-world asset tokenization in the commodities space. CEO of the combined company Henry McPhie commented, 'This is a landmark moment for Streamex and a major step forward for the tokenization industry. Joining forces with BioSig and entering the public markets will position us to accelerate growth, scale our technology and expand our influence within the tokenization and commodities industries. I am extremely proud of what the Streamex and BioSig team has been able to accomplish so far and am excited for what is to come.' Strategic Advisor Additions: Mr. Frank Giustra has agreed to join as a Strategic Investor and Advisor on Commodities. Founder of Wheaton Precious Metals ($37B) Founder of GoldCorp, acquired by Newmont ($57B) Founder of LionsGate Films ($2B) Mr. Mathew August has agreed to join as a Strategic Advisor on US Capital Markets. Executive Chairman of Atlas Capital Partners a New York, NY based single family office investment firm and merchant bank Active Venture Capitalist with significant investments within the Defense Tech, FinTech, Aerospace and other diversified industries About Streamex Exchange Corporation Streamex is a real-world asset (RWA) tokenization company focused in the commodities space. With the goal to bring commodity markets on chain, Streamex has developed primary issuance and exchange infrastructure that will revolutionize commodity finance. Streamex is led by a group of highly successful and seasoned executives from financial, commodities and blockchain industries. Streamex believes the future of finance lies in tokenization, innovative investment strategies, and decentralized markets. By merging advanced financial technologies with blockchain transparency, Streamex has created infrastructure and solutions that enhance liquidity, accessibility, and efficiency. Streamex's goal is to bridge the gap between traditional finance and the digital economy, unlocking new opportunities for investors and institutions worldwide. Terms of Share Exchange In exchange for 100% of their shares of Streamex, existing Streamex shareholders will be entitled to receive 75% of the fully diluted BioSig common stock outstanding on the date of the share exchange agreement. Initially, upon the closing, pursuant to Nasdaq listing rules, the Streamex shareholders will be entitled to receive 19.9% of the outstanding BioSig common stock pre-transaction. BioSig will then seek a vote of its current shareholders to approve the transaction; if such approval is obtained, the Streamex shareholders will have the right to receive in the aggregate the full number of shares of BioSig common stock equaling 75% of the fully diluted BioSig common stock pre-transaction. After shareholder approval, if obtained, current BioSig shareholders and holders of common stock equivalents will hold 25% of the fully diluted BioSig common stock outstanding. Effective immediately, the Board of Directors of the combined company will be comprised of six members, four designated by BioSig, who are Anthony Amato, Chris Baer, Donald F. Browne, Steven E. Abelman and two designated by Streamex, who are Mr. McPhie and Mr. Lekstrom (who will also be Chairman of the combined company's board). To the extent required by NASDAQ's change of control rules and regulations, the combined company will file an initial listing application for its common stock. Forward Looking Statements This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond our control. It is possible that our actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements, depending on factors including whether we will be able to realize the benefits of the transaction described herein, whether shareholder approval of the transaction will be obtained and whether we will be able to maintain compliance with Nasdaq's listing criteria in connection with the described transaction and otherwise. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in forward-looking statements, see our filings with the Securities and Exchange Commission, including the section titled 'Risk Factors' in our Annual Report on Form 10-K, filed with the SEC on April 15, 2025. We assume no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise, except as required by law.
Yahoo
7 days ago
- Business
- Yahoo
BioSig Technologies signs definitive share exchange agreement with Streamex
BioSig Technologies (BSGM) announced it has signed a definitive share exchange agreement with Streamex Exchange, a privately held company specializing in the tokenization of real-world assets, with a focus on bringing commodities on-chain. 'The signing of the definitive agreement represents a major milestone for both Streamex and BioSig, propelling the business combination forward, and fast-tracking the growth of Streamex's tokenization business. During this transaction, Streamex has made significant progress with some very exciting developments expected to be shared in the coming weeks,' the company stated. BioSig's CEO Anthony Amato commented, 'After a year marked by intense focus, disciplined execution, and steadfast commitment, I'm pleased to announce that we have signed a definitive agreement to combine with Streamex. This marks a pivotal milestone in our ongoing strategy to restore and build long-term shareholder value. This journey hasn't been without its challenges-but it has also been defined by toughness, learning, and progress. But today, we enter what promises to be the most transformational chapter in our company's history. I want to thank our incredible employees, our leadership team, and our board of directors for their unwavering dedication and resilience throughout this journey. And to our shareholders: this is the moment we've been working toward. We believe this business combination significantly strengthens the foundation of your investment and positions us for sustained momentum and future growth.' Henry McPhie, incoming CEO of the combined company added, 'Since announcing the LOI for the transaction, we've received an overwhelmingly positive response from the market, reflecting strong investor confidence in the value and potential of this transaction. With the signing of the definitive agreement, we're thrilled to move ahead with the BioSig team to complete the combination and bring Streamex to the public market.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on BSGM: Disclaimer & DisclosureReport an Issue BioSig Technologies Delays Q1 2025 Filing BioSig Technologies Regains Nasdaq Compliance BioSig Technologies enters LOI to merge with Streamex Exchange BioSig Technologies Delays Form 10-K Filing BioSig Technologies confirms full compliance with Nasdaq requirements Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-05-2025
- Business
- Yahoo
BioSig Stock Surges Following Share Exchange Deal With Streamex
BioSig Technologies, Inc. BSGM recently entered into a definitive share exchange agreement with Streamex Exchange Corporation (Streamex), a private company focused on the tokenization of real-world assets. This strategic move marks BioSig's entry into the rapidly growing blockchain and digital asset sector, with an emphasis on bringing commodity markets on-chain. With this agreement, BioSig is positioning itself to tap into the growing global commodities market through innovative blockchain solutions. This merger not only diversifies BioSig's business model but also aligns it with the future of decentralized finance, unlocking new opportunities for growth and market relevance in the digital age. Following the announcement, shares of the company soared 24.4% and closed at $5.28 on Friday. In the year-to-date period, BSGM's shares have gained 254.4% against the industry's 10.5% decline. The S&P 500 decreased 1.9% in the same time frame. This deal can significantly boost BSGM's business in the long run by transforming its core identity from a traditional medtech company into a diversified player in the blockchain and digital asset space. By integrating Streamex's platform for real-world asset tokenization, especially in commodities, BSGM gains access to a high-growth, trillion-dollar market far beyond its original scope. This diversification can open new revenue streams, attract fintech-focused investors, and enhance the company's strategic value. Meanwhile, BSGM currently has a market capitalization of $144.1 million. The company expects its earnings to improve 73.3% in 2025 year over year. Image Source: Zacks Investment Research Real-world asset tokenization is the process of converting physical or traditional assets, such as real estate, commodities, or artwork, into digital tokens on a blockchain. These tokens represent ownership or rights to the underlying asset, enabling easier transfer, fractional ownership, and increased liquidity. BSGM is likely to benefit from this deal by gaining access to Streamex's innovative blockchain technology and expertise in real-world asset tokenization, allowing it to diversify beyond medical technology into the fast-growing digital asset and commodities markets. Under the terms of the agreement, Streamex will become a wholly owned subsidiary of BioSig through a share exchange transaction. All outstanding shares of Streamex will be exchanged for new shares of BioSig common stock. Streamex shareholders will receive 75% of BioSig's fully diluted common stock in exchange for all Streamex shares. At closing, they will get 19.9% initially (per Nasdaq rules), and the remaining shares, up to 75%, will be issued after BioSig shareholders approve the deal. Post-approval, existing BioSig shareholders will retain 25% ownership in the combined company. Per a report by MarketsandMarkets, the global tokenization market size was valued at $2.3 billion in 2021, and it is projected to reach $5.6 billion by the end of 2026 at a CAGR of 19.0% during the forecast period. The tokenization market is driven by the growing demand for increased liquidity, transparency, and accessibility in traditional asset markets. Advances in blockchain technology enable the digitization of real-world assets, making it easier to trade, fractionalize, and transfer ownership globally. BSGM carries a Zacks Rank #2 (Buy) at present. Some other top-ranked stocks in the broader medical space that have announced quarterly results are CVS Health Corporation CVS, Integer Holdings Corporation ITGR and AngioDynamics ANGO. CVS Health, carrying a Zacks Rank of 2, reported first-quarter 2025 adjusted earnings per share (EPS) of $2.25, beating the Zacks Consensus Estimate by 31.6%. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Revenues of $94.59 billion outpaced the consensus mark by 1.8%. CVS Health has a long-term estimated growth rate of 11.4%. Its earnings surpassed estimates in each of the trailing four quarters, with an average surprise of 18.1%. Integer Holdings reported first-quarter 2025 adjusted EPS of $1.31, beating the Zacks Consensus Estimate by 3.2%. Revenues of $437.4 million surpassed the Zacks Consensus Estimate by 1.3%. It currently sports a Zacks Rank of 1. Integer Holdings has a long-term estimated growth rate of 18.4%. ITGR's earnings surpassed estimates in three of the trailing four quarters and missed once, the average surprise being 2.8%. AngioDynamics, currently sporting a Zacks Rank #1, reported a third-quarter fiscal 2025 adjusted EPS of 3 cents against the Zacks Consensus Estimate of a 13-cent loss. Revenues of $72 million beat the Zacks Consensus Estimate by 2%. ANGO has an estimated fiscal 2026 earnings growth rate of 27.8% compared with the S&P 500 Composite's 10.5% growth. AngioDynamics' earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 70.9%. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AngioDynamics, Inc. (ANGO) : Free Stock Analysis Report CVS Health Corporation (CVS) : Free Stock Analysis Report Integer Holdings Corporation (ITGR) : Free Stock Analysis Report Biosig Technologies, Inc. (BSGM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
25-05-2025
- Business
- Yahoo
BioSig Technologies, Inc. (BSGM) Turns to Tokenization with Streamex Acquisition
BioSig Technologies, Inc. (NASDAQ:BSGM) has entered a definitive share exchange agreement with Streamex Exchange Corp, which initiates a bold shift from medical technology to blockchain-powered real-world asset (RWA) tokenization. As per the agreement, Streamex will become a wholly owned subsidiary with its shareholders expected to hold 75% of BioSig's fully diluted common stock, pending shareholder approval. A cardiac surgeon demonstrating a simulated ablation procedure with a signal processing platform. In the combined entity, Streamex's co-founder, Henry McPhie, will step in as CEO, and Morgan Lekstrom will take on the role of Chairman. Current BioSig Technologies, Inc. (NASDAQ:BSGM) CEO Anthony Amato will transition to a board role, signaling the company's retreat from its original medical tech identity. Complying with regulations, the company has initially issued 19.9% of shares to Streamex investors and awaits full approval. The transaction has attracted strategic advisors with high profiles, including Frank Giustra, the founder of Wheaton Precious Metals and GoldCorp, indicating the noteworthiness of the company's entry into the $142.85 trillion global commodity sector. Leveraging its vertically integrated infrastructure, Streamex can gain a competitive edge with tokenization poised to address inefficiencies in commodity trading and settlement. On the other hand, BioSig Technologies, Inc. (NASDAQ:BSGM)'s radical shift introduces considerable uncertainty. Existing shareholder equity is diluted, and the company is also exposed to the operational risks inherent in shifting industries. Additionally, the technical specifications regarding Streamex's blockchain framework have also not been disclosed yet. Notably, while the institutional transaction in BioSig Technologies, Inc. (NASDAQ:BSGM) has increased by 218.41%, the insider transaction remains neutral at 0.00% over the last six months. BSGM could be a potential investment opportunity. But our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BSGM and that has 100x upside potential, check out our report about the READ NEXT: 10 Unstoppable Dividend Stocks to Buy Now and 11 Oversold Global Stocks to Buy According to Hedge Funds Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
